Phenobarbital 64.8 mg Tablet, 100-count
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Barbiturates and derivatives class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
Phenobarbital is used to control seizures. Phenobarbital is also used to relieve anxiety. It is also used to prevent withdrawal symptoms in people who are dependent ('addicted'; feel a need to continue taking the medication) on another barbiturate medication and are going to stop taking the medication. Phenobarbital is in a class of medications called barbiturates. It works by slowing activity in the brain.
Read the full MedlinePlus article ↗- Phenobarbital is mainly used to control seizures — including generalized tonic-clonic seizures (sometimes called grand mal seizures) and partial seizures. It's also used as a sedat...
- What is phenobarbital actually used for?
- Please don't stop it on your own. Phenobarbital can cause physical dependence, and stopping it suddenly — especially after taking it for a while — can trigger serious withdrawal sy...
- Can I just stop taking phenobarbital if I feel better?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Phenobarbital — tap one for details:
Phenobarbital may be associated with lower levels of 11 nutrients — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
💊 What it looks like
Where does this data come from?
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII OP1R32D61U
Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
-
UNII EWQ57Q8I5X
Lactose monohydrate is a natural sugar derived from milk. It serves as a filler and binder in tablets and capsules, helping create the proper size, texture, and consistency of the medicine.
-
UNII 70097M6I30
Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
-
UNII ETJ7Z6XBU4
Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
-
UNII 5856J3G2A2
A starch-based powder made from potatoes and processed with sodium. It acts as a disintegrant, helping the tablet or capsule break apart quickly in the stomach so the medicine can be absorbed.
5 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.102 | $10.16 / 100 tablets |
| Medicaid paysCMS SDUD · 12 mo | $0.2921 | $29.21 / 100 tablets |
| Medicare drug plans payPart D · Q2 2026 | $0.1530 | $15.30 / 100 tablets |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Phenobarbital 64.8 mg 00603-5167-21 | Par | 100 tablets | $0.102 | — | Availability likely | — |
| Phenobarbital 64.8 mg 13517-0627-01 | e5 | 100 tablets | $0.102 | — | Discontinued | — |
| Phenobarbital 64.8 mg 13811-0306-10 | Trigen | 100 tablets | $0.102 | — | Availability likely | — |
| Phenobarbital 64.8 mg 16571-0667-01 | Rising | 100 tablets | $0.102 | — | Availability likely | — |
| Phenobarbital 64.8 mg 69367-0213-01 | Westminster | 100 tablets | $0.102 | — | Discontinued | — |
| Phenobarbital 64.8 mg 69367-0443-01 | Westminster | 100 tablets | $0.102 | — | Availability likely | — |
| Phenobarbital 64.8 mg 69367-0627-01 | Westminster | 100 tablets | $0.102 | — | Availability likely | — |
| Phenobarbital 64.8 mgthis 75826-0141-10 | WINDER | 100 tablets | $0.102 | — | Availability likely | — |
| Phenobarbital 64.8 mg 51672-5328-01 | Sun | 100 tablets | — | — | FDA listed | — |
| Phenobarbital 64.8 mg 58118-0576-08 | Clinical | 30 tablets | — | — | FDA listed | — |
| Phenobarbital 64.8 mg 62135-0407-60 | Chartwell | 60 tablets | — | — | FDA listed | — |
| Phenobarbital 64.8 mg 63629-2402-01 | Bryant | 1000 tablets | — | — | FDA listed | — |
| Phenobarbital 64.8 mg 63629-2403-01 | Bryant | 100 tablets | — | — | FDA listed | — |
| Phenobarbital 64.8 mg 64950-0576-01 | Genus | 100 tablets | — | — | FDA listed | — |
| Phenobarbital 64.8 mg 67046-0780-03 | Coupler | 30 tablets | — | — | FDA listed | — |
| Phenobarbital 64.8 mg 67046-1434-03 | Coupler | 30 tablets | — | — | FDA listed | — |
| Phenobarbital 64.8 mg 70518-4215-00 | REMEDYREPACK | 30 tablets | — | — | FDA listed | — |
| Phenobarbital 64.8 mg 70752-0163-10 | QUAGEN | 100 tablets | — | — | FDA listed | — |
| Phenobarbital 64.8 mg 71205-0849-00 | Proficient | 100 tablets | — | — | FDA listed | — |
| Phenobarbital 64.8 mg 71205-0892-00 | Proficient | 100 tablets | — | — | FDA listed | — |
| Phenobarbital 64.8 mg 72162-1167-00 | Bryant | 1000 tablets | — | — | FDA listed | — |
| Phenobarbital 64.8 mg 72162-1265-00 | Bryant | 1000 tablets | — | — | FDA listed | — |
| Phenobarbital 64.8 mg 82804-0984-00 | Proficient | 100 tablets | — | — | FDA listed | — |
| Phenobarbital 64.8 mg 70518-4717-00 | REMEDYREPACK | 100 tablets | — | — | FDA listed | — |
| Phenobarbital 64.8 mg 62135-0557-90 | Chartwell | 90 tablets | — | — | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
🗺️ Medicaid utilization & spend
💊 Medicaid utilization by pack size
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
🔬 Reported adverse events (FAERS)
Top reported reactions
Reporter sex
Serious outcomes
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Status |
|---|---|---|---|---|---|
| 75826-0141-00 | 1000 TABLET in 1 BOTTLE, PLASTIC (75826-141-00) | $0.1016 / ea | $101.59 | 2019-06-11 | Active |
| 75826-0141-10 You're viewing this | 100 TABLET in 1 BOTTLE, PLASTIC (75826-141-10) | $0.1016 / ea | $10.16 | 2019-06-11 | Active |
You're viewing the smallest of 2 pack sizes for this product.
This pack effectively ties for the lowest per-ea cost of the 2 priced pack sizes ($0.1016 NADAC).
In Medicaid, this is the most-dispensed pack of this product — about 91% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in NDC 75826-0141-10?
What is the difference between NDC 75826-0141-10 and NDC 75826-0141-00?
What NDC number is used to bill for this package of Phenobarbital 64.8 mg Tablet?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
🧭 About this NDC listing & data coverage
Listed without an FDA application
This product's marketing category indicates it is marketed without an approved FDA application (no NDA, ANDA, or BLA on file). Having an NDC does not by itself establish FDA approval — the NDC Directory is a listing system, not an approval decision. Approval-linked data such as Orange Book therapeutic-equivalence ratings therefore does not apply.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | ✓ Available |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | ✓ Available |
Questions about this listing
Is this NDC FDA-approved?
Is the NDC printed on the package the same as the 11-digit billing NDC?
What do the three segments of this NDC mean?
Is this package still being marketed?
Does this product come in other package sizes?
Who lists this product with the FDA?
Do I need a prescription for this product?
Where does this data come from?
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Phenobarbital Tablets, USP are indicated for use as a sedative or anticonvulsant.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Oral Sedative Dose, Adults: 30 to 120 mg daily in 2 or 3 divided doses. Children: 6 mg/kg of body weight daily in 3 divided doses. Oral Hypnotic Dose, Adults: 100 to 320 mg. Oral Anticonvulsant Dose, Adults: 50 to 100 mg 2 or 3 times daily. Children: 15 to 50 mg 2 or 3 times daily.
⛔ Contraindications ▾
CONTRAINDICATIONS Phenobarbital is contraindicated in patients who are hypersensitive to barbiturates. In such patients, severe hepatic damage can occur from ordinary doses and is usually associated with dermatitis and involvement of parenchymatous organs. A personal or familial history of acute intermittent porphyria represents one of the few absolute contraindications to the use of barbiturates.
Phenobarbital is also contraindicated in patients with marked impairment of liver function, or respiratory disease in which dyspnea or obstruction is evident. It should not be administered to persons with known previous addiction to the sedative/hypnotic group, since ordinary doses may be ineffectual and may contribute to further addiction.
⚠️ Warnings ▾
WARNINGS In small doses, the barbiturates may increase the reaction to painful stimuli. Taken by themselves, the barbiturates cannot be relied upon to relieve pain or even to produce sedation or sleep in the presence of severe pain.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS The following adverse reactions have been reported: CNS Depression: Residual sedation or "hangover," drowsiness, lethargy, and vertigo. Emotional disturbances and phobias may be accentuated. In some persons, barbiturates such as phenobarbital repeatedly produce excitement rather than depression, and the patient may appear to be inebriated.
Like other nonanalgesic hypnotic drugs, barbiturates, such as phenobarbital, when given in the presence of pain, may cause restlessness, excitement, and even delirium. Rarely, the use of barbiturates results in localized or diffused myalgic, neuralgic, or arthritic pain, especially in psychoneurotic patients with insomnia. The pain may appear in paroxysms, is most intense in the early morning hours, and is most frequently located in the region of the neck, shoulder girdle, and upper limbs.
Symptoms may last for days after the drug is discontinued. Respiratory/Circulatory: Respiratory depression, apnea, circulatory collapse. Allergic: Acquired hypersensitivity to barbiturates consists chiefly in allergic reactions that occur especially in persons who tend to have asthma, urticaria, angioedema, and similar conditions.
Hypersensitivity reactions in this category include localized swelling, particularly of the eyelids, cheeks, or lips, and erythematous dermatitis. Rarely, exfoliative dermatitis (e.g., Stevens-Johnson syndrome and toxic epidermal necrolysis) may be caused by phenobarbital and can prove fatal. The skin eruption may be associated with fever, delirium, and marked degenerative changes in the liver and other parenchymatous organs.
In a few cases, megaloblastic anemia has been associated with the chronic use of phenobarbital. Other: Nausea and vomiting; headache. To report SUSPECTED ADVERSE REACTIONS, contact Winder Laboratories, LLC at 1-770-307-0703, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
🔄 Drug Interactions ▾
Drug Interactions Phenobarbital in combination with alcohol, tranquilizers, and other central nervous system depressants has additive depressant effects, and the patient should be so advised. Patients taking this drug should be warned not to exceed the dosage recommended by their physician. Toxic effects and fatalities have occurred following overdoses of phenobarbital alone and in combination with other central nervous system depressants.
Caution should be exercised in prescribing unnecessarily large amounts of phenobarbital for patients who have a history of emotional disturbances or suicidal ideation or who have misused alcohol and other CNS drugs (see OVERDOSAGE ).
🤰 Pregnancy ▾
Usage in Pregnancy Pregnancy Category B Reproduction studies have been performed in animals and have revealed no evidence of impaired fertility or harm to the fetus due to phenobarbital. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed and under the supervision of a physician .
🆘 Overdosage ▾
OVERDOSAGE The signs and symptoms of barbiturate poisoning are referable especially to the central nervous system and the cardiovascular system. Moderate intoxication resembles alcoholic inebriation. In severe intoxication, the patient is comatose, the level of reflex activity conforming in a general way to the intensity of the central depression.
The deep reflexes may persist for some time despite coexistent coma. The Babinski sign is often positive. The EEG may be of the "burst-suppression" type, with brief periods of electrical silence.
The pupils may be constricted and react to light, but late in the course of barbiturate poisoning they may show hypoxic paralytic dilatation. Respiration is affected early. Breathing may be either slow or rapid and shallow; Cheyne-Stokes rhythm may be present.
Respiratory minute volume is diminished, and hypoxia and respiratory acidosis may develop. The blood pressure falls, owing partly to depression of medullary vasomotor centers; partly to a direct action of the drug on the myocardium, sympathetic ganglia, and vascular smooth muscle; partly to hypoxia. The patient thus develops a typical shock syndrome, with a weak and rapid pulse, cold and clammy skin, and a rise in the hematocrit.
Respiratory complications (atelectasis, pulmonary edema, and bronchopneumonia) and renal failure are much dreaded and not infrequent concomitant of severe barbiturate poisoning. There is usually hypothermia, sometimes with temperatures as low as 32°C. Treatment General management should consist of symptomatic and supportive therapy, including gastric lavage, administration of intravenous fluids, and maintenance of blood pressure, body temperature and adequate respiratory exchange.
Dialysis will increase the rate of removal of barbiturates from the body fluids. Antibiotics may be required to control pulmonary complications.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Phenobarbital, a long-acting barbiturate, is a central nervous system depressant. In ordinary doses, the drug acts as a sedative and anticonvulsant. Its onset of action occurs within 30 minutes, and the duration of action ranges from 5 to 6 hours. It is detoxified in the liver.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Phenobarbital Tablets, USP 15 mg: White, Round Tablet; Debossed WL on one side and 136 on the other side. Bottles of 90 tablets NDC 75826-136-90 Bottles of 100 tablets NDC 75826-136-10 Bottles of 500 tablets NDC 75826-136-50 Bottles of 1000 tablets NDC 75826-136-00 Phenobarbital Tablets, USP 16.2 mg (¼ grain): White, Round, Scored Tablet; Debossed WL on one side and 137 on the other side. Bottles of 90 tablets NDC 75826-137-90 Bottles of 100 tablets NDC 75826-137-10 Bottles of 500 tablets NDC 75826-137-50 Bottles of 1000 tablets NDC 75826-137-00 Phenobarbital Tablets, USP 30 mg: White, Round, Scored Tablet; Debossed WL on one side and 138 on the other side.
Bottles of 90 tablets NDC 75826-138-90 Bottles of 100 tablets NDC 75826-138-10 Bottles of 500 tablets NDC 75826-138-50 Bottles of 1000 tablets NDC 75826-138-00 Phenobarbital Tablets, USP 32.4 mg (½ grain): White, Round, Scored Tablet; Debossed WL on one side and 139 on the other side. Bottles of 90 tablets NDC 75826-139-90 Bottles of 100 tablets NDC 75826-139-10 Bottles of 500 tablets NDC 75826-139-50 Bottles of 1000 tablets NDC 75826-139-00 Phenobarbital Tablets, USP 60 mg: White, Round Tablet; Debossed WL on one side and 140 on the other side.
Bottles of 90 tablets NDC 75826-140-90 Bottles of 100 tablets NDC 75826-140-10 Bottles of 500 tablets NDC 75826-140-50 Bottles of 1000 tablets NDC 75826-140-00 Phenobarbital Tablets, USP 64.8 mg (1 grain): White, Round, Scored Tablet; Debossed WL on one side and 141 on the other side. Bottles of 90 tablets NDC 75826-141-90 Bottles of 100 tablets NDC 75826-141-10 Bottles of 500 tablets NDC 75826-141-50 Bottles of 1000 tablets NDC 75826-141-00 Phenobarbital Tablets, USP 97.2 mg (1½ grain): White, Round, Scored Tablet; Debossed WL on one side and 142 on the other side.
Bottles of 90 tablets NDC 75826-142-90 Bottles of 100 tablets NDC 75826-142-10 Bottles of 500 tablets NDC 75826-142-50 Bottles of 1000 tablets NDC 75826-142-00 Phenobarbital Tablets, USP 100 mg: White, Round, Scored Tablet; Debossed WL on one side and 143 on the other side. Bottles of 90 tablets NDC 75826-143-90 Bottles of 100 tablets NDC 75826-143-10 Bottles of 500 tablets NDC 75826-143-50 Bottles of 1000 tablets NDC 75826-143-00 Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect from light and moisture.
Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.
📦 Storage and Handling ▾
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect from light and moisture. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.
📋 Description ▾
DESCRIPTION The barbiturates are nonselective central nervous system (CNS) depressants primarily used as sedative-hypnotics. In subhypnotic doses, they are also used as anticonvulsants. The barbiturates and their sodium salts are subject to control under the Federal Controlled Substances Act.
Phenobarbital is a barbituric acid derivative for oral administration and occurs as a white, odorless, slightly bitter powder that is soluble in chloroform, freely soluble in alcohol or ether, and slightly soluble in water. Its saturated solution has a pH of about 5.6. Chemically, it is 5-ethyl-5-phenylbarbituric acid with the molecular formula C 12 H 12 N 2 O 3 (232.24).
The structural formula is as follows: Each Phenobarbital Tablet, USP contains 15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 64.8 mg, 97.2 mg, or 100 mg of phenobarbital, USP. Inactive ingredients are as follows: Microcrystalline Cellulose; Lactose Monohydrate; Sodium Starch Glycolate, Type-A; Colloidal Silicon Dioxide; Magnesium Stearate Chemical Structure
💬 Information for Patients ▾
Information for Patients Phenobarbital may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a car or operating machinery. The patient should be cautioned accordingly.